HCT Versus CT in Elderly AML

Inclusion Criteria: * Age ≥ 60years and ≤ 75 years * primary or secondary AML as defined by WHO or refractory anemia with excess of blasts (RAEB) * First complete remission following one or two cycles of induction chemotherapy * Chemotherapy was administered according to current participating cooperative group protocols * Karnofsky score ≥ 70 * Written informed consent Exclusion Criteria: * AML FAB M3 * HIV positivity * Participation in another clinical trial without prior consent of the coordinating investigator, patients may exceptionally take part in a further study only if * The second study exclusively concerns induction therapy * Consolidation cycle one and two are given according to the accredited study group policy * No investigational drugs are used post registration for the HCT vs CT in eldery AML study. * Documentation for the HCT vs CT in eldery AML study is not compromised. Second hand data from foreign study is not accepted